{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T13:27:17Z","timestamp":1785245237365,"version":"3.55.0"},"reference-count":43,"publisher":"American Veterinary Medical Association (AVMA)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["javma"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec>\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To evaluate the efficacy of doxorubicin for treatment of histiocytic sarcoma (HS) in dogs, whether administered as the sole treatment or as an adjunct to surgery or radiation therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>31 client-owned dogs with localized or disseminated HS examined between 2003 and 2017.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>PROCEDURES<\/jats:title>\n<jats:p>Medical records were reviewed retrospectively, and data were collected. The Kaplan-Meier method was used to estimate time-to-progression from the date of first doxorubicin administration and survival time from initial diagnosis. Factors that could be associated with poorer outcomes with doxorubicin treatment were analyzed with log-rank tests.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>RESULTS<\/jats:title>\n<jats:p>The objective response rate (ORR) was 26%. When stratified by disease status, dogs with localized and disseminated forms experienced 43% and 21% ORRs, respectively. Median time to progression after initiating doxorubicin treatment (n = 30 dogs) was 42 days. Median survival time from initial diagnosis to death (n = 29 dogs) was 169 days. Complete responses were obtained in only 2 dogs that had localized disease and received multimodality therapy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Benefits of doxorubicin administration in canine HS are modest, with a limited ORR and delay in tumor progression, and are comparable to effects attained with other single-agent regimens.<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/javma.21.11.0498","type":"journal-article","created":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T18:17:39Z","timestamp":1662056259000},"page":"1827-1833","source":"Crossref","is-referenced-by-count":12,"title":["Doxorubicin for treatment of histiocytic sarcoma in dogs: 31 cases (2003\u20132017)"],"prefix":"10.2460","volume":"260","author":[{"given":"Rhiannon M.","family":"Doka","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Suter","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Mastromauro","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Hess","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1272","reference":[{"issue":"5","key":"ref1","series-title":"Vet Pathol","first-page":"632","article-title":"Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages","volume":"43","author":"Moore PF","year":"2006","unstructured":"Moore PF, Affolter VK, Vernau W. Canine hemophagocytic histiocytic sarcoma: a proliferative disorder of CD11d+ macrophages. Vet Pathol. 2006;43(5):632\u2013645. doi:10.1354\/vp.43-5-63216966440"},{"issue":"4","key":"ref2","series-title":"Cancer Control","first-page":"290","article-title":"Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment","volume":"21","author":"Dalia S","year":"2014","unstructured":"Dalia S, Shao H, Sagatys E, Cualing H, Sokol L. Dendritic cell and histiocytic neoplasms: biology, diagnosis, and treatment. Cancer Control. 2014;21(4):290\u2013300. doi:10.1177\/10732748140210040525310210"},{"issue":"4","key":"ref3","series-title":"Cancer Treat Rev","first-page":"320","article-title":"Langerhans cell sarcoma: a systematic review","volume":"41","author":"Howard JE","year":"2015","unstructured":"Howard JE, Dwivedi RC, Masterson L, Jani P. Langerhans cell sarcoma: a systematic review. Cancer Treat Rev. 2015;41(4):320\u2013331. doi:10.1016\/j.ctrv.2015.02.01125805533"},{"issue":"1","key":"ref4","series-title":"Crit Rev Oncol Hematol","first-page":"1","article-title":"Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases","volume":"65","author":"De Pas T","year":"2008","unstructured":"De Pas T, Spitaleri G, Pruneri G,  Dendritic cell sarcoma: an analytic overview of the literature and presentation of original five cases. Crit Rev Oncol Hematol. 2008;65(1):1\u20137. doi:10.1016\/j.critrevonc.2007.06.00317658269"},{"issue":"2","key":"ref5","series-title":"Crit Rev Oncol Hematol","first-page":"253","article-title":"Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series","volume":"88","author":"Saygin C","year":"2013","unstructured":"Saygin C, Uzunaslan D, Ozguroglu M, Senocak M, Tuzuner N. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;88(2):253\u2013271. doi:10.1016\/j.critrevonc.2013.05.00623755890"},{"issue":"1","key":"ref6","series-title":"J Clin Exp Hematop","first-page":"1","article-title":"Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification","volume":"53","author":"Takahashi E","year":"2013","unstructured":"Takahashi E, Nakamura S. Histiocytic sarcoma: an updated literature review based on the 2008 WHO classification. J Clin Exp Hematop. 2013;53(1):1\u20138. doi:10.3960\/jslrt.53.123801128"},{"issue":"4","key":"ref7","series-title":"Cancers (Basel)","first-page":"2275","article-title":"Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the Moffitt Cancer Center experience over the last twenty five years","volume":"6","author":"Dalia S","year":"2014","unstructured":"Dalia S, Jaglal M, Chervenick P, Cualing H, Sokol L. Clinicopathologic characteristics and outcomes of histiocytic and dendritic cell neoplasms: the Moffitt Cancer Center experience over the last twenty five years. Cancers (Basel). 2014;6(4):2275\u20132295. doi:10.3390\/cancers604227525405526"},{"issue":"16","key":"ref8","series-title":"Eur J Cancer","first-page":"2413","article-title":"Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas","volume":"51","author":"Gounder M","year":"2015","unstructured":"Gounder M, Desai V, Kuk D,  Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas. Eur J Cancer. 2015;51(16):2413\u20132422. doi:10.1016\/j.ejca.2015.06.109"},{"issue":"6","key":"ref9","series-title":"J Vet Med Sci","first-page":"1059","article-title":"Malignant histiocytosis with multiple skin lesions in a dog","volume":"55","author":"Uno Y","year":"1993","unstructured":"Uno Y, Momoi Y, Watari T,  Malignant histiocytosis with multiple skin lesions in a dog. J Vet Med Sci. 1993;55(6):1059\u20131061. doi:10.1292\/jvms.55.1059"},{"issue":"1-2","key":"ref10","series-title":"Aust Vet J","first-page":"37","article-title":"Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas","volume":"95","author":"Moore AS","year":"2017","unstructured":"Moore AS, Taylor DP, Reppas G, Frimberger AE. Chemotherapy for dogs with lymph node metastasis from histiocytic sarcomas. Aust Vet J. 2017;95(1-2):37\u201340. doi:10.1111\/avj.1252228124419"},{"issue":"5","key":"ref11","series-title":"Cancer Chemother Pharmacol","first-page":"410","article-title":"Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors","volume":"39","author":"Vail DM","year":"1997","unstructured":"Vail DM, Kravis LD, Cooley AJ, Chun R, MacEwen EG. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors. Cancer Chemother Pharmacol. 1997;39(5):410\u2013416 doi:10.1007\/s0028000505919054954"},{"issue":"1","key":"ref12","series-title":"Vet Comp Oncol","first-page":"77","article-title":"Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs","volume":"16","author":"Kezer KA","year":"2018","unstructured":"Kezer KA, Barber LG, Jennings SH. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs. Vet Comp Oncol. 2018;16(1):77\u201380. doi:10.1111\/vco.1231428419676"},{"issue":"1","key":"ref13","series-title":"Vet Comp Oncol","first-page":"E30","article-title":"Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy","volume":"16","author":"Mason SL","year":"2018","unstructured":"Mason SL, Finotello R, Blackwood L. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy. Vet Comp Oncol. 2018;16(1):E30\u2013E37. doi:10.1111\/vco.1232928621004"},{"issue":"6","key":"ref14","series-title":"J Vet Intern Med","first-page":"1528","article-title":"Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma","volume":"24","author":"Rassnick KM","year":"2010","unstructured":"Rassnick KM, Moore AS, Russell DS,  Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Intern Med. 2010;24(6):1528\u20131531. doi:10.1111\/j.1939-1676.2010.0588.x21155191"},{"issue":"1","key":"ref15","series-title":"J Vet Intern Med","first-page":"121","article-title":"CCNU for the treatment of dogs with histiocytic sarcoma","volume":"21","author":"Skorupski KA","year":"2007","unstructured":"Skorupski KA, Clifford CA, Paoloni MC,  CCNU for the treatment of dogs with histiocytic sarcoma. J Vet Intern Med. 2007;21(1):121\u2013126. doi:10.1111\/j.1939-1676.2007.tb02937.x17338159"},{"issue":"11","key":"ref16","series-title":"J Am Vet Med Assoc","first-page":"1230","article-title":"Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997\u20132012)","volume":"246","author":"Wouda RM","year":"2015","unstructured":"Wouda RM, Miller ME, Chon E, Stein TJ. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997\u20132012). J Am Vet Med Assoc. 2015;246(11):1230\u20131237. doi:10.2460\/javma.246.11.123025970220"},{"issue":"2","key":"ref17","series-title":"J Vet Intern Med","first-page":"219","article-title":"Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors","volume":"18","author":"Poirier VJ","year":"2004","unstructured":"Poirier VJ, Hershey AE, Burgess KE,  Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors. J Vet Intern Med. 2004;18(2):219\u2013222. doi:10.1111\/j.1939-1676.2004.tb00164.x15058774"},{"issue":"4","key":"ref18","series-title":"Vet Comp Oncol","first-page":"658","article-title":"Primary pulmonary histiocytic sarcoma in dogs: a retrospective analysis of 37 cases (2000\u20132015)","volume":"16","author":"Marlowe KW","year":"2018","unstructured":"Marlowe KW, Robat CS, Clarke DM,  Primary pulmonary histiocytic sarcoma in dogs: a retrospective analysis of 37 cases (2000\u20132015). Vet Comp Oncol. 2018;16(4):658\u2013663. doi:10.1111\/vco.1243730246460"},{"issue":"7","key":"ref19","series-title":"J Small Anim Pract","first-page":"425","article-title":"Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma","volume":"56","author":"Cannon C","year":"2015","unstructured":"Cannon C, Borgatti A, Henson M, Husbands B. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma. J Small Anim Pract. 2015;56(7):425\u2013429. doi:10.1111\/jsap.1235425828786"},{"issue":"1","key":"ref20","series-title":"Proceedings of the 30th Annual Veterinary Cancer Society Conference","first-page":"e12","article-title":"Efficacy of doxorubicin for histiocytic sarcoma in dogs","volume":"9","author":"Higuchi T","year":"2011","unstructured":"Higuchi T, Dervisis N, Kitchell B. Efficacy of doxorubicin for histiocytic sarcoma in dogs. Abstract in: Proceedings of the 30th Annual Veterinary Cancer Society Conference. Veterinary Cancer Society; 2011;9(1):e12."},{"issue":"4","key":"ref21","series-title":"J Comp Pathol","first-page":"347","article-title":"Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats","volume":"151","author":"Pierezan F","year":"2014","unstructured":"Pierezan F, Mansell J, Ambrus A, Rodrigues Hoffmann A. Immunohistochemical expression of ionized calcium binding adapter molecule 1 in cutaneous histiocytic proliferative, neoplastic and inflammatory disorders of dogs and cats. J Comp Pathol. 2014;151(4):347\u2013351. doi:10.1016\/j.jcpa.2014.07.00325172051"},{"issue":"3","key":"ref22","series-title":"Vet Comp Oncol","first-page":"176","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen SM","year":"2015","unstructured":"Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document. Vet Comp Oncol. 2015;13(3):176\u2013183. doi:10.1111\/vco.1203223534501"},{"issue":"4","key":"ref23","series-title":"Vet Comp Oncol","first-page":"195","article-title":"Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","volume":"2","year":"2004","unstructured":"Veterinary Co-operative Oncology Group (VCOG). Veterinary Co-operative Oncology Group - Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol. 2004;2(4):195\u2013213. doi:10.1111\/j.1476-5810.2004.0053b.x19379294"},{"issue":"5","key":"ref24","series-title":"J Vet Med Sci","first-page":"661","article-title":"Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan","volume":"76","author":"Takahashi M","year":"2014","unstructured":"Takahashi M, Tomiyasu H, Hotta E,  Clinical characteristics and prognostic factors in dogs with histiocytic sarcomas in Japan. J Vet Med Sci. 2014;76(5):661\u2013666. doi:10.1292\/jvms.13-041424441652"},{"issue":"4","key":"ref25","series-title":"Vet Comp Oncol","first-page":"1171","article-title":"Clinical prognostic factors in canine histiocytic sarcoma","volume":"15","author":"Dervisis NG","year":"2017","unstructured":"Dervisis NG, Kiupel M, Qin Q, Cesario L. Clinical prognostic factors in canine histiocytic sarcoma. Vet Comp Oncol. 2017;15(4):1171\u20131180. doi:10.1111\/vco.1225227334037"},{"issue":"8","key":"ref26","series-title":"J Small Anim Pract","first-page":"461","article-title":"Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition?","volume":"58","author":"Lenz JA","year":"2017","unstructured":"Lenz JA, Furrow E, Craig LE, Cannon CM. Histiocytic sarcoma in 14 miniature schnauzers - a new breed predisposition? J Small Anim Pract. 2017;58(8):461\u2013467. doi:10.1111\/jsap.1268828543363"},{"issue":"1","key":"ref27","series-title":"Vet Pathol","first-page":"74","article-title":"Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs","volume":"39","author":"Affolter VK","year":"2002","unstructured":"Affolter VK, Moore PF. Localized and disseminated histiocytic sarcoma of dendritic cell origin in dogs. Vet Pathol. 2002;39(1):74\u201383. doi:10.1354\/vp.39-1-7412102221"},{"issue":"6","key":"ref28","series-title":"Vet Radiol Ultrasound","first-page":"E66","article-title":"Canine histiocytic sarcoma presenting as a target lesion on brain magnetic resonance imaging and as a solitary pulmonary mass","volume":"59","author":"Hicks J","year":"2018","unstructured":"Hicks J, Barber R, Childs B, Kirejczyk SG, Uhl EW. Canine histiocytic sarcoma presenting as a target lesion on brain magnetic resonance imaging and as a solitary pulmonary mass. Vet Radiol Ultrasound. 2018;59(6):E66\u2013E70. doi:10.1111\/vru.1250228419635"},{"issue":"2","key":"ref29","series-title":"J Vet Intern Med","first-page":"607","article-title":"Histiocytic sarcoma with central nervous system involvement in dogs: 19 cases (2006\u20132012)","volume":"29","author":"Mariani CL","year":"2015","unstructured":"Mariani CL, Jennings MK, Olby NJ,  Histiocytic sarcoma with central nervous system involvement in dogs: 19 cases (2006\u20132012). J Vet Intern Med. 2015;29(2):607\u2013613. doi:10.1111\/jvim.12554"},{"issue":"4","key":"ref30","series-title":"J Vet Med Sci","first-page":"593","article-title":"Histological and immunohistochemical studies on primary intracranial canine histiocytic sarcomas","volume":"78","author":"Thongtharb A","year":"2016","unstructured":"Thongtharb A, Uchida K, Chambers JK, Kagawa Y, Nakayama H. Histological and immunohistochemical studies on primary intracranial canine histiocytic sarcomas. J Vet Med Sci. 2016;78(4):593\u2013599. doi:10.1292\/jvms.15-062726668164"},{"issue":"2","key":"ref31","series-title":"Vet Radiol Ultrasound","first-page":"E17","article-title":"Imaging diagnosis\u2014spinal cord histiocytic sarcoma in a dog","volume":"56","author":"Taylor A","year":"2015","unstructured":"Taylor A, Eichelberger B, Hodo C, Cooper J, Porter B. Imaging diagnosis\u2014spinal cord histiocytic sarcoma in a dog. Vet Radiol Ultrasound. 2015;56(2):E17\u2013E20. doi:10.1111\/vru.12135"},{"issue":"2","key":"ref32","series-title":"Vet Radiol Ultrasound","first-page":"178","article-title":"MR imaging of histiocytic sarcoma of the canine brain","volume":"50","author":"Tamura S","year":"2009","unstructured":"Tamura S, Tamura Y, Nakamoto Y, Ozawa T, Uchida K. MR imaging of histiocytic sarcoma of the canine brain. Vet Radiol Ultrasound. 2009;50(2):178\u2013181. doi:10.1111\/j.1740-8261.2009.01512.x19400464"},{"issue":"1","key":"ref33","series-title":"Vet Pathol","first-page":"66","article-title":"The diagnosis and prognosis of synovial tumors in dogs: 35 cases","volume":"39","author":"Craig LE","year":"2002","unstructured":"Craig LE, Julian ME, Ferracone JD. The diagnosis and prognosis of synovial tumors in dogs: 35 cases. Vet Pathol. 2002;39(1):66\u201373. doi:10.1354\/vp.39-1-6612102220"},{"issue":"2","key":"ref34","series-title":"Vet Comp Oncol","first-page":"139","article-title":"Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy","volume":"7","author":"Skorupski KA","year":"2009","unstructured":"Skorupski KA, Rodriguez CO, Krick EL, Clifford CA, Ward R, Kent MS. Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy. Vet Comp Oncol. 2009;7(2):139\u2013144. doi:10.1111\/j.1476-5829.2009.00186.x19453368"},{"issue":"2","key":"ref35","series-title":"Vet Comp Oncol","first-page":"63","article-title":"Histiocytic sarcomas in Flat-Coated Retrievers: a summary of 37 cases (November 1998-March 2005)","volume":"4","author":"Fidel J","year":"2006","unstructured":"Fidel J, Schiller I, Hauser B,  Histiocytic sarcomas in Flat-Coated Retrievers: a summary of 37 cases (November 1998-March 2005). Vet Comp Oncol. 2006;4(2):63\u201374. doi:10.1111\/j.1476-5810.2006.00090.x19754816"},{"issue":"1","key":"ref36","series-title":"J Am Vet Med Assoc","first-page":"90","article-title":"Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma","volume":"239","author":"Klahn SL","year":"2011","unstructured":"Klahn SL, Kitchell BE, Dervisis NG. Evaluation and comparison of outcomes in dogs with periarticular and nonperiarticular histiocytic sarcoma. J Am Vet Med Assoc. 2011;239(1):90\u201396. doi:10.2460\/javma.239.1.9021718201"},{"issue":"1","key":"ref37","series-title":"Vet Comp Oncol","first-page":"44","article-title":"Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells","volume":"10","author":"Hafeman SD","year":"2012","unstructured":"Hafeman SD, Varland D, Dow SW. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells. Vet Comp Oncol. 2012;10(1):44\u201356. doi:10.1111\/j.1476-5829.2011.00274.x"},{"issue":"1","key":"ref38","series-title":"BMC Cancer","first-page":"237","article-title":"A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies","volume":"18","author":"Takada M","year":"2018","unstructured":"Takada M, Parys M, Gregory-Bryson E, Vilar Saavedra P, Kiupel M, Yuzbasiyan-Gurkan V. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies. BMC Cancer. 2018;18(1):237. doi:10.1186\/s12885-018-4132-029490634"},{"issue":"6","key":"ref39","series-title":"J Vet Med Sci","first-page":"677","article-title":"Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines","volume":"77","author":"Asada H","year":"2015","unstructured":"Asada H, Tomiyasu H, Goto-Koshino Y, Fujino Y, Ohno K, Tsujimoto H. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines. J Vet Med Sci. 2015;77(6):677\u2013684. doi:10.1292\/jvms.14\u2013041525715778"},{"issue":"7","key":"ref40","series-title":"Cell Death Dis","first-page":"e179","article-title":"Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters","volume":"2","author":"Saxena M","year":"2011","unstructured":"Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011;2(7):e179. doi:10.1038\/cddis.2011.6121734725"},{"key":"ref41","series-title":"Mol Cancer","first-page":"314","article-title":"Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin","volume":"9","author":"Shukla A","year":"2010","unstructured":"Shukla A, Hillegass JM, MacPherson MB,  Blocking of ERK1 and ERK2 sensitizes human mesothelioma cells to doxorubicin. Mol Cancer. 2010;9:314. doi:10.1186\/1476-4598-9-31421159167"},{"issue":"3","key":"ref42","series-title":"Vet Sci","first-page":"150","article-title":"Mechanisms of drug resistance in veterinary oncology - a review with an emphasis on canine lymphoma","volume":"2","author":"Zandvliet M","year":"2015","unstructured":"Zandvliet M, Teske E. Mechanisms of drug resistance in veterinary oncology - a review with an emphasis on canine lymphoma. Vet Sci. 2015;2(3):150\u2013184. doi:10.3390\/vetsci203015029061939"},{"issue":"7","key":"ref43","series-title":"Am J Vet Res","first-page":"680","article-title":"Effect of a two-base insertion mutation of the TP53 gene on expression of p53 protein in canine histiocytic sarcoma cells","volume":"80","author":"Asada H","year":"2019","unstructured":"Asada H, Tomiyasu H, Goto-Koshino Y, Ohno K, Tsujimoto H. Effect of a two-base insertion mutation of the TP53 gene on expression of p53 protein in canine histiocytic sarcoma cells. Am J Vet Res. 2019;80(7):680\u2013688. doi:10.2460\/ajvr.80.7.68031246118"}],"container-title":["Journal of the American Veterinary Medical Association"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/260\/14\/javma.21.11.0498.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/260\/14\/javma.21.11.0498.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/javma\/260\/14\/javma.21.11.0498.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T15:17:46Z","timestamp":1727450266000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/javma\/260\/14\/javma.21.11.0498.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":43,"journal-issue":{"issue":"14"},"URL":"https:\/\/doi.org\/10.2460\/javma.21.11.0498","relation":{},"ISSN":["0003-1488"],"issn-type":[{"value":"0003-1488","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,1]]}}}